# Weiguo Su

Source: https://onco.cc/people/su-weiguo/  
OnCo record `su-weiguo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US.

## Summary

A former Pfizer chemist who joined Hutchmed in 2005 as head of research and became CEO in 2022; his team designed fruquintinib (FDA approval 2023 via Takeda), the selective MET inhibitor savolitinib (partnered with AstraZeneca) and surufatinib, the first Chinese-discovered small molecules to reach global markets.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Also known as: 苏慰国
- Tags: china
- Role: CEO and Chief Scientific Officer, Hutchmed
- Specialisms: Kinase inhibitor discovery; Medicinal chemistry

## Sources

- Hutchmed: https://www.hutch-med.com/

## Connected records

- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Savolitinib](https://onco.cc/drugs/savolitinib/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/su-weiguo.json